CDX2 and colorectal carcinoma: Compared to CDX2, the loss of SATB2 showed a considerably higher prognostic impact in univariate analyses (log-rank test) of the overall cohort and in nearly all clinicopathological subscenarios of CRC, in which CDX2 mostly showed at best minimal prognostic impact in our cohort.